Gerard Griffioen
Technik-/Wissenschafts-/F&E-Leiter bei reMYND NV
Profil
Gerard Griffioen is currently the Chief Scientific Officer-Drug Discovery at reMYND NV.
He previously worked as a Principal at the University of Vienna and Katholieke Universiteit Leuven.
Dr. Griffioen obtained a doctorate degree from Vrije Universiteit Amsterdam in 1996.
Aktive Positionen von Gerard Griffioen
| Unternehmen | Position | Beginn |
|---|---|---|
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Gerard Griffioen
| Unternehmen | Position | Ende |
|---|---|---|
| Katholieke Universiteit Leuven | Corporate Officer/Principal | - |
| University of Vienna | Corporate Officer/Principal | - |
Ausbildung von Gerard Griffioen
| Vrije Universiteit Amsterdam | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
